CN102267998B - 新型抗寄生虫吡嗪异喹啉衍生物 - Google Patents

新型抗寄生虫吡嗪异喹啉衍生物 Download PDF

Info

Publication number
CN102267998B
CN102267998B CN201110154047.XA CN201110154047A CN102267998B CN 102267998 B CN102267998 B CN 102267998B CN 201110154047 A CN201110154047 A CN 201110154047A CN 102267998 B CN102267998 B CN 102267998B
Authority
CN
China
Prior art keywords
isoquinoline derivative
pyrazine
schistosomiasis
parasitic
1mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110154047.XA
Other languages
English (en)
Other versions
CN102267998A (zh
Inventor
杨越
孙德群
杨春华
罗敏
张凌子
孙丽
张文龙
苟招聘
王锦
胡长燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong University Weihai
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201110154047.XA priority Critical patent/CN102267998B/zh
Priority to CN201510117838.3A priority patent/CN104788457B/zh
Priority to CN201510117197.1A priority patent/CN104844606B/zh
Publication of CN102267998A publication Critical patent/CN102267998A/zh
Application granted granted Critical
Publication of CN102267998B publication Critical patent/CN102267998B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种如结构通式式I的吡嗪异喹啉衍生物,以及对日本血吸虫有杀灭作用的包括结构通式如式I的吡嗪异喹啉衍生物组分的药物组合物和药物。

Description

新型抗寄生虫吡嗪异喹啉衍生物
技术领域
本发明涉及一种治疗寄生虫疾病的新型吡嗪异喹啉衍生物,特别涉及一种治疗寄生虫疾病包括但不限于血吸虫、绦虫、囊虫、华支睾吸虫、肺吸虫和姜片虫引起的人畜共患性疾病的包括一种吡嗪异喹啉衍生物组分的药物组合和药物。
背景技术
血吸虫病是由于感染三种主要的血吸虫(曼氏血吸虫、埃及血吸虫和日本血吸虫)而引起的流行病。40年来,吡喹酮仍然是广泛用于防治人和动物各种血吸虫成虫感染的唯一有效药物。由于它的大量和长期使用,目前已经产生药物抗性;而针对血吸虫幼虫感染的血吸虫病至今仍无有效药物治疗。据世界卫生组织披露全球有2亿人感染血吸虫病,有约6亿人受感染威胁,血吸虫病的高发病人数有2千万,每年有至少280000人死于血吸虫病。而卫生部和国家发改委下发的“全国综合治理血吸虫病‘十五’计划”数据表明,我国目前尚未控制血吸虫病传播的108个县集中分布在湖沼地区和大山区,动物宿主众多,钉螺分布广泛,受环境因素影响很大,防治工作特别困难,重复感染依然十分严重,疫情处于很不稳定状态。面对如此众多的血吸虫病感染人群仅吡喹酮一种化学药物是很不相称的,因此亟需研制新的抗血吸虫药物。
发明内容
一种通式I的化合物,其药用上适用于人和动物的各种盐,及其各种异构体和氮氧化合物。结构通式如式I,
其中,
A是不饱和环,包括苯环,吡啶环和氮氧偶极吡啶环;
B是饱和氮杂环,包括五元,六元,和七元饱和氮杂环,B环上可以由C1-C4烷基取代,或形成3-5元饱和并环;
C是饱和氮杂环,包括五元,六元,和七元饱和氮杂环,可以是酮或非酮化合物;
D是饱和环,包括三元,四元,五元,六元,和七元饱和环;
A选自如下基团:
B+C选自如下基团:
D选自如下基团:
其中优选的但不限于的化合物为:
本发明化合物出乎意料地显示适于治疗寄生虫疾病,尤其包括血吸虫、绦虫、囊虫、华支睾吸虫、肺吸虫、姜片虫引起的人畜共患性疾病.本发明也涉及将上文定义的通式I的化合物,将其药学上接受的酸或碱加成盐,包括季盐,立体化学异构形式,N-氧化合物形式用做药,以及下述任何药物组合物在制备用于治疗寄生虫疾病,包括血吸虫、绦虫、囊虫、华支睾吸虫、肺吸虫、姜片虫引起的人畜共患性疾病的药物中的用途。
因此,本发明另一方面提供一种治疗患有寄生虫疾病(包括血吸虫疾病)的方法,该方法包括治疗有效量的本发明化合物或药物组合物给予患者或患蓄。
本发明也涉及组合物,其包含药学上可接受的载体和作为活性成分的治疗有效量的本发明化合物。本发明化合物可被调配成用于给药目的的不同药物形式。作为适当组合物的例证的是全身给药药物通常所采用的所有组合物。为制备本发明药物组合物,有效量的特定化合物(任选以加成盐形式)作为活性成分与药物可接受载体紧密组合,取决于给药所需的制剂形式,所述载体可采取多种形式。这些药物组合物宜为特别是适合口服给药或胃肠外注射的单一剂量形式。例如,在制备口服剂型的组合物时,在口服液体制剂如混悬剂,糖浆剂,乳剂和溶液剂的情况下,可以采用任何平常的药物介质,如水,乙二醇,油,醇等;或者在粉末剂,丸剂,胶囊剂和片剂的情况下,采用固体载体例如淀粉,糖,高岭土,稀释剂,粘合剂等。
取决于给药的方式,所述药物组合优选包括0.05-99%重量,更优选0.1-70%重量的活性成分,以及优选1-99.95%重量,更优选30-99.9%重量的药学上可接受的载体,所有百分比均基于总组合物计算。
具体实施方式
实施例一典型化合物1-3的制备:
向装有磁力搅拌的圆底烧瓶中加入1-1(188mg,1mmol),环己甲酸(128mg,1mmol),EDCI(211mg,1.1mmol)和DMAP(139mg,1.1mmol)。室温下搅拌过夜,用1%盐酸水和饱和碳酸钠溶液交替洗涤,最后用水洗。无水硫酸镁干燥后浓缩得白色固体.Mp132-135(277mg,收率93%)。
向装有磁力搅拌的圆底烧瓶中加入1-1(188mg,1mmol),环戊甲酸(114mg,1mmol),EDCI(211mg,1.1mmol)和DMAP(139mg,1.1mmol)。室温下搅拌过夜,用1%盐酸水和饱和碳酸钠溶液交替洗涤,最后用水洗。无水硫酸镁干燥后浓缩得白色固体Mp128-130(256mg,收率90.14%)。
向装有磁力搅拌的圆底烧瓶中加入1-1(188mg,1mmol),环庚甲酸(142mg,1mmol),EDCI(211mg,1.1mmol)和DMAP(139mg,1.1mmol)。室温下搅拌过夜,用1%盐酸水和饱和碳酸钠溶液交替洗涤,最后用水洗。无水硫酸镁干燥后浓缩得白色固体.Mp137-139(287mg,收率92%)。
实施例二典型化合物10-12的制备:
向装有磁力搅拌的圆底烧瓶中加入10-1(232mg,1mmol),环己甲酸(128mg,1mmol),EDCI(211mg,1-1mmol)和DMAP(139mg,1.1mmol)。室温下搅拌过夜,用1%盐酸水和饱和碳酸钠溶液交替洗涤,最后用水洗。无水硫酸镁干燥后浓缩得白色固体.Mp143-146(324mg,收率95%)。
向装有磁力搅拌的圆底烧瓶中加入10-1(232mg,1mmol),环庚甲酸(142mg,1mmol),EDCI(211mg,1.1mmol)和DMAP(139mg,1.1mmol)。室温下搅拌过夜,用1%盐酸水和饱和碳酸钠溶液交替洗涤,最后用水洗。无水硫酸镁干燥后浓缩得白色固体.Mp138--141(295mg,收率90%)。
向装有磁力搅拌的圆底烧瓶中加入10-1(232mg,1mmol),环庚甲酸(142mg,1mmol),EDCI(211mg,1.1mmol)和DMAP(139mg,1.1mmol)。室温下搅拌过夜,用1%盐酸水和饱和碳酸钠溶液交替洗涤,最后用水洗。无水硫酸镁干燥后浓缩得白色固体.Mp149-153(316mg,收率89%)。
实施例三生物学效应
测定化合物抗日本血吸虫的体外方法:成虫体外培养:采集活的雄性成虫置于DMEM培养液(10条/3ml/皿)中,分组加药。每皿分别加入化合物各3ul,终浓度为50(mol/ml,对照组加DMS03(1(参考其他实验组加药最高剂量)。加药后充分摇匀,放入37℃、5%CO:培养箱中。培养过夜(16h)后用生理盐水洗涤虫体3次,加入新鲜培养液,在体视显微镜下观察培养.24h~72h后的血吸虫活力状态,并影像记录。结果见表1。
表1
化合物 虫数 死亡率等级 化合物 虫数 死亡率等级
1 20 A 35 20 A
4 20 A 37 20 A
7 20 A 40 20 A
13 20 A 43 20 A
18 20 A 46 20 A
19 20 A 50 20 A
21 20 A 54 20 A
22 20 A 57 20 A
24 20 A 62 20 A
28 20 A 64 20 A
29 20 A 66 20 A
30 20 A 67 20 A
34 20 A 69 20 A
表中死亡率等级:A为100-80%。

Claims (4)

1.一种吡嗪异喹啉衍生物,其特征在于,所述吡嗪异喹啉衍生物为如化学结构式通式I的化合物;其中,D是如式II、III、IV或V中的一种;
2.根据权利要求1所述的吡嗪异喹啉衍生物,其特征在于,所述吡嗪异喹啉衍生物选自如化学结构式a和如化学结构式b的化合物中的一种;
3.一种对日本血吸虫有杀灭作用的药物组合物,其特征在于,所述组合物包含药学上可接受的载体,所述药物组合物的活性成分包括如权利要求1或2所述的吡嗪异喹啉衍生物。
4.一种对日本血吸虫有杀灭作用的药物,其特征在于,所述药物的活性成分包括如权利要求1或2所述的吡嗪异喹啉衍生物。
CN201110154047.XA 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物 Expired - Fee Related CN102267998B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201110154047.XA CN102267998B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物
CN201510117838.3A CN104788457B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物
CN201510117197.1A CN104844606B (zh) 2011-05-31 2011-05-31 抗寄生虫吡嗪异喹啉衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110154047.XA CN102267998B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510117838.3A Division CN104788457B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物
CN201510117197.1A Division CN104844606B (zh) 2011-05-31 2011-05-31 抗寄生虫吡嗪异喹啉衍生物

Publications (2)

Publication Number Publication Date
CN102267998A CN102267998A (zh) 2011-12-07
CN102267998B true CN102267998B (zh) 2015-05-13

Family

ID=45050475

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201110154047.XA Expired - Fee Related CN102267998B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物
CN201510117838.3A Expired - Fee Related CN104788457B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物
CN201510117197.1A Expired - Fee Related CN104844606B (zh) 2011-05-31 2011-05-31 抗寄生虫吡嗪异喹啉衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510117838.3A Expired - Fee Related CN104788457B (zh) 2011-05-31 2011-05-31 新型抗寄生虫吡嗪异喹啉衍生物
CN201510117197.1A Expired - Fee Related CN104844606B (zh) 2011-05-31 2011-05-31 抗寄生虫吡嗪异喹啉衍生物

Country Status (1)

Country Link
CN (3) CN102267998B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321088A (zh) * 2011-08-03 2012-01-18 威海秀水药物研发有限公司 一种新型抗血吸虫化合物
CN113754666A (zh) * 2021-09-07 2021-12-07 凯美克(上海)医药科技有限公司 一种苯并吡嗪类化合物及其合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661489A (en) * 1983-07-16 1987-04-28 Beecham Group P.L.C. Benzazepines, and their use as anthelminthics
DE3619030A1 (de) * 1986-06-06 1987-12-10 Bayer Ag Topisch anwendbare zubereitungen
CN1683346A (zh) * 2005-03-01 2005-10-19 江苏工业学院 吡喹酮合成工艺

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661489A (en) * 1983-07-16 1987-04-28 Beecham Group P.L.C. Benzazepines, and their use as anthelminthics
DE3619030A1 (de) * 1986-06-06 1987-12-10 Bayer Ag Topisch anwendbare zubereitungen
CN1683346A (zh) * 2005-03-01 2005-10-19 江苏工业学院 吡喹酮合成工艺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胡玉琴,等.血吸虫病化学预防药物4H-吡嗪并〔2, 1-a〕异喹啉衍生物的合成.《中国药物化学杂志》.1997,第7卷(第1期),第38页合成路线. *

Also Published As

Publication number Publication date
CN104788457A (zh) 2015-07-22
CN104844606B (zh) 2017-03-01
CN104788457B (zh) 2017-08-25
CN102267998A (zh) 2011-12-07
CN104844606A (zh) 2015-08-19

Similar Documents

Publication Publication Date Title
WO2017162108A1 (zh) 一种柱芳烃类复合物、其制备方法、药物组合物和用途
CN101616917A (zh) 吡啶并[2,3-d]嘧啶以及它们作为激酶抑制剂的用途
CN104736202B (zh) 用于抑制肌成束蛋白的方法
KR20170113546A (ko) 옥사티아진-유사 화합물의 제조방법
CN108530444A (zh) 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
CN102267998B (zh) 新型抗寄生虫吡嗪异喹啉衍生物
CN106632133B (zh) 噻唑类衍生物及其制备方法与应用
Huang et al. Bioactivity and mechanism of action of sanguinarine and its derivatives in the past 10 years
CN107820495A (zh) 靶向epha4的配体结合域的新型epha4抑制剂
CN106937953A (zh) 氧化苦参碱在制备抗肿瘤药物增敏剂中的应用
CN102432607A (zh) 一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
TWI542348B (zh) 含4-乙醯基-安卓奎諾-b之組合物用於製備抑制癌細胞生長之藥物的用途
CN106668012A (zh) 含氮杂环芳香酯类化合物在制备抗柯萨奇病毒b3型的药物中的应用
JP2022542449A (ja) Stat3二機能性リン酸化部位を標的とするトリアロマティック化合物のクラスおよびその応用
US11970499B1 (en) Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors
US11891396B1 (en) 5-substituted pyrido[3″,4″:4′,5′]pyrrolo[3′,2′:4,5]imidazo[1,2-a]pyrazine compounds as CK2 inhibitors
US10064843B2 (en) Bis-amide derivative and use thereof
US11851430B1 (en) Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors
US11964975B1 (en) 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][2,6]naphthyridine compounds as CK2 inhibitors
WO2021223664A1 (en) Methods for treating coronavirus infections
US11897881B1 (en) Substituted pyrido[3,4-b]indole-3-carboxylic acids as CK2 inhibitors
US11891390B1 (en) 3-substituted amino-2-arylpyrrolo[2,3-c]pyridines as CK2 inhibitors
CN110384694B (zh) 一种xenicane型二萜化合物在制备抗氧化神经保护药物中的应用
US11820779B1 (en) Aza-podophyllotoxin analogues as potential anti-cancer agents
US11952378B1 (en) Pyrrolo[2,3-c]isoquinoline-1,2-dione compounds as CK2 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SHANDONG UNIVERSITY (WEIHAI)

Free format text: FORMER OWNER: SUN DEQUN

Effective date: 20150710

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150710

Address after: 264209 Weihai Cultural Road West, Shandong, No. 180

Patentee after: Shandong University, Weihai

Address before: 264209 innovation building, hi tech Zone, Shandong, Weihai 507

Patentee before: Sun Dequn

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150513

Termination date: 20170531